Document Detail

Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker.
MedLine Citation:
PMID:  20736143     Owner:  NLM     Status:  MEDLINE    
As interleukin-15 (IL-15) has been implicated in the pathophysiology of rheumatoid arthritis, we analysed the serum IL-15 (sIL-15) levels in healthy subjects and patients with early arthritis to establish a cut-off point that might serve to define elevated sIL-15. This is an initial step to determine whether sIL-15 has the potential for use as a biomarker for patients with early arthritis. The IL-15 concentration was measured in serum obtained from 161 healthy controls and from 174 patients with early arthritis, and the relationship between the expression of the two IL-15 mRNA variants and the sIL-15 levels was also assessed. In healthy controls, the median sIL-15 value was 0.83 [interquartile range (IQR) 0-8.68] pg/mL; there was no significant difference in the sIL-15 values according to gender [median level in males was 1.99 (IQR: 0-8.68) pg/mL and in females 0.50 (0-8.25) pg/mL: p = 0.821]. Moreover, sIL-15 levels did not correlate with age (r = 0.033, p = 0.685), and they did not display a clear circadian rhythm in healthy donors, with the median values for IL-15 close to zero at each time tested. In the light of these findings, we considered that sIL-15 was elevated if its concentration was above 20 pg/mL, since this cut-off point corresponded to the 90th percentile for this healthy population. We found that 30% of the patients with early arthritis had sIL-15 values > 20 pg/mL. The levels of sIL-15 did not correlate with disease duration in early arthritis patients, nor did they fluctuate with changes in disease activity over the follow-up period. In addition, the high level of sIL15 in patients was not associated with alterations in the alternative splicing of the IL-15 mRNA, favouring the variant that produces the protein with a long signal peptide for secretion. Serum IL-15 levels were increased in a subpopulation of patients with early arthritis, indicating that this measure may serve as a biomarker for this condition. Further studies will be necessary to determine whether the clinical evolution or response to treatment of patients with high sIL-15 levels differs.
Amalia Lamana; Ana M Ortiz; José M Alvaro-Gracia; Belén Díaz-Sánchez; Jesús Novalbos; Rosario García-Vicuña; Isidoro González-Alvaro
Related Documents :
1022873 - Pneumococcal arthritis.
2918003 - Cranial subluxation of the odontoid process in rheumatoid arthritis.
18808723 - The clinical overlap between functional dyspepsia and irritable bowel syndrome based on...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-24
Journal Detail:
Title:  European cytokine network     Volume:  21     ISSN:  1952-4005     ISO Abbreviation:  Eur. Cytokine Netw.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-14     Completed Date:  2011-01-20     Revised Date:  2012-08-31    
Medline Journal Info:
Nlm Unique ID:  9100879     Medline TA:  Eur Cytokine Netw     Country:  France    
Other Details:
Languages:  eng     Pagination:  186-94     Citation Subset:  IM    
Rheumatology Service, Hospital Universitario La Princesa, IIS La Princesa, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Arthritis / blood*
Base Sequence
Biological Markers / blood*
Circadian Rhythm
DNA Primers
Immunoenzyme Techniques
Interleukin-15 / blood*,  genetics
Middle Aged
RNA, Messenger / genetics
Reference Values
Reverse Transcriptase Polymerase Chain Reaction
Reg. No./Substance:
0/Biological Markers; 0/DNA Primers; 0/Interleukin-15; 0/RNA, Messenger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Oral magnesium supplementation improves vascular function in elderly diabetic patients.
Next Document:  Superimposed segmental dermatomyositis: an emerging new paradigm.